The BrainChip Holdings Ltd (ASX: BRN) share price is in focus after the company reported a 19% lift in half-year revenue to US$1.22 million, with a net loss after tax of US$12.0 million as it accelerates on commercialising its neuromorphic AI technology.

A man sits at a desk with a phone in one hand, his other hand on his chin and studies a computer screen in front of him with what appears to be cryptocurrency data on both screens.

Image source: Getty Images

What did BrainChip report?

  • Revenue of US$1,222,745, up 19% from 1H 2025
  • Net loss after tax of US$12,015,897 (1H 2025: US$9,360,251)
  • Operating expenses increased 33% to US$13,647,140
  • Cash and cash equivalents of US$20,304,971 as at 30 June 2026
  • No interim dividend declared

What else do investors need to know?

BrainChip achieved a significant operational milestone by shipping the first production batch of 2,000 AKD1500 neuromorphic processors, marking the transition from pre-production to commercial-scale manufacturing. The company is also developing AKD1500-based hardware platforms to support faster customer adoption.

During the half, BrainChip signed new intellectual property (IP) licensing deals with EDGEAI and ASICLAND, opening up new streams for potential licensing and royalty revenue. The ecosystem expanded through a new partnership with MicroIP, while dedicated product platforms for defence, industrial AI, and signal analytics were advanced.

Costs rose as BrainChip invested in R&D, commercialisation efforts, and supporting its next-generation AKD2500 chip—still tracking for a late-2026 development milestone. The company’s financing facility with LDA Capital concluded during the period, with all obligations substantially settled.

What’s next for BrainChip?

BrainChip is focused on broadening commercial deployment of its Akida neuromorphic technology across defence, industrial, and edge AI markets. The company expects further product shipments, ecosystem partnerships, and customer integrations in the coming months.

See also  BCI Minerals: SOP pilot plant contract awarded

Development of the AKD2500 chip and BrainChip’s Generative AI program remain key priorities, with internal demonstrations of its GenAI platform targeted by year-end. Management says groundwork is being laid for increased commercial and licensing revenue ahead of anticipated larger-scale customer uptake.

BrainChip share price snapshot

Over the past 12 months, BrainChip shares have declined 33%, trailing the All Ordinaries Index (ASX: XAO), which has risen 1% over the same period.

View Original Announcement


Source link

Author

Shin John
Shin JohnYtv Market News
Share-market news writer and analyst with deep experience covering equities, commodities, forex, and cryptocurrencies for readers in the USA, UK, Canada, and Australia. Ytv Market News delivers timely market updates, practical trading insights, and clear explanations of macro and company-level catalysts that move prices. Combines on-the-ground financial reporting with technical analysis, using concise charts and actionable ideas to help investors and traders make smarter decisions.